What Voltaren SR Treats: Main Uses and Benefits

Voltaren SR (Diclofenac sustained-release) is used for symptomatic management, providing supportive relief across several areas where symptoms create interference with daily stability. This extended-release formulation is generally used to help ease the pain, tenderness, swelling, and stiffness associated with various inflammatory conditions.

The medication is applicable in conditions marked by heightened physiological stress, including:

• Chronic inflammatory joint disorders such as rheumatoid arthritis and osteoarthritis.
• Acute musculoskeletal events such as pain following physical trauma or surgical procedures.
• Specific episodic inflammations like acute gout manifestations and primary dysmenorrhoea.

The prolonged action helps support day-to-day comfort by contributing to easing the overall symptom load. The sustained-release formulation is primarily relevant when supportive symptom management is appropriate, as it assists with maintaining functional stability during periods of symptomatic discomfort.

---

Quick Fact: Support for Symptoms of Stiffness and Inflammation

Voltaren SR is commonly used to help with symptoms related to inflammatory or irritative states, assisting with maintaining functional stability by helping to ease pain and associated swelling.

Regulatory References

1. NIH MedlinePlus overview

Eligibility and Contraindications

The use of Voltaren SR (diclofenac sustained-release) is strictly defined by regulatory guidelines, which establish clear restrictions and contraindications based on patient health status and age.

Contraindications (Must Not Use):

• Allergy/Sensitivity: Patients with a known hypersensitivity to diclofenac, aspirin, or any other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), as this can precipitate asthma, urticaria, or anaphylactic-like reactions.
• Cardiovascular: Those in the setting of coronary artery bypass graft (CABG) surgery and patients with established congestive heart failure (NYHA Class II-IV), ischemic heart disease, or peripheral arterial disease.
• Gastrointestinal: Individuals with active gastric or intestinal ulceration, bleeding, or perforation.
• Organ Function: Patients with severe renal failure or hepatic failure.
• Pregnancy: Women in the last trimester of pregnancy (starting at 30 weeks gestation) due to fetal risk.

Eligibility Restrictions:

• Pediatric Population: Not generally recommended for use in children and adolescents, particularly those under 16 years of age, as safety and efficacy have not been established.
• Geriatric Population: Elderly patients require special caution and should be prescribed the lowest effective dose for the shortest possible duration due to an increased risk of serious gastrointestinal and cardiovascular events.
• Pre-existing Conditions: Caution is required in patients with a history of gastrointestinal disease, uncontrolled hypertension, or established cardiovascular risk factors. Use is not recommended in women who are planning to conceive or are breastfeeding.

Interactions with other medicines and products

This medication's interaction profile is categorized based on combinations that pose an increased risk of adverse events and those that alter drug concentrations or therapeutic efficacy.

Interacting Product Category	Official Interaction Constraint
Other NSAIDs/Salicylates (e.g., Aspirin)	Not generally recommended; increases risk of serious gastrointestinal adverse events.
Anticoagulants/Antiplatelet Agents (e.g., Warfarin)	Increased risk of serious bleeding; requires close monitoring.
Antihypertensive Agents (e.g., ACE inhibitors, Diuretics)	May diminish the blood pressure-lowering effect; requires blood pressure monitoring.
Lithium, Digoxin	May increase the plasma concentrations of these medicines; requires monitoring of serum levels to prevent toxicity.
Methotrexate, Cyclosporine, Tacrolimus	May increase the toxicity (e.g., hematologic, nephrotoxic) of the co-administered medicine; use with caution.
CYP2C9 Inhibitors (e.g., Voriconazole)	Increases plasma concentration of this medicine; requires use with caution and potential clinical adjustment.

Co-administration with other non-steroidal anti-inflammatory medicines (NSAIDs) or salicylates is generally not recommended due to an elevated risk of severe gastrointestinal issues, including bleeding and perforation. For drugs that influence blood clotting, such as anticoagulants and antiplatelet agents, the combined use significantly raises the risk of serious bleeding. When combined with most blood pressure-lowering drugs, the efficacy of the antihypertensive agent may be diminished, necessitating close monitoring of blood pressure. Additionally, this medicine can alter the body's clearance of drugs like Lithium and Digoxin, potentially leading to increased blood levels and toxicity, which mandates therapeutic drug monitoring.

Voltaren SR's active ingredient, diclofenac, functions as a non-selective, reversible inhibitor of the cyclooxygenase (COX) enzyme isoforms, specifically COX-1 and COX-2.

These membrane-bound enzymes catalyze the conversion of arachidonic acid—a phospholipid-derived substrate—into various lipid mediators known as eicosanoids. The most significant eicosanoids affected by this inhibition are the prostaglandins and thromboxanes.

Diclofenac's interaction with the enzyme active site results in a dose-dependent reduction in the systemic biosynthesis of these potent paracrine signaling molecules. The subsequent decrease in prostaglandin concentration modulates key physiological processes, including reduced local tissue vasodilation and altered vascular permeability, which are components of the local tissue response to various stimuli. This action restricts signal transduction pathways that regulate these initial physiological changes.

How to Use Voltaren SR

The administration of Voltaren SR (Diclofenac Sustained-Release) follows standardized parameters defining its oral use and specific handling requirements.

Administration Scope

Instruction	Detail
Route of administration	The sustained-release tablet is intended for oral administration only.
Dosing schedule	The standard adult regimen is typically 100 mg once daily for extended-release forms, or may permit 75 mg once or twice daily for certain prolonged-release products, adhering to the principle of using the lowest effective dose. The maximum daily dose for the standard 100 mg regimen is typically 100 mg per day.
Timing in relation to meals	The tablet may be taken with or after food to enhance tolerability, or it may be taken without food.
Age-group administration rules	Older Adults: Treatment should be initiated at the lowest effective dose. Pediatric: This sustained-release formulation is not suitable for children as specific dose recommendations are absent for this delivery method.
Special procedural conditions	The tablet must be swallowed whole and not be cut, crushed, chewed, or split. This action is critical to ensure the sustained-release mechanism delivers the medication over the intended duration.

Connection to the Overall Use Protocol

The standard instructions establish a precise use protocol centered on maintaining the integrity of the sustained-release mechanism via the oral route. The requirement for a once-daily frequency and the specific dosage ranges define a standardized regimen. Furthermore, the high-level guidance to use the lowest dose for the shortest duration sets the operational framework for its use in chronic conditions.

Recent Clinical Evidence

Studies on Drug Properties

Research has explored the drug's properties that are thought to influence pain and inflammation in the body. Studies evaluated the drug for its association with changes in pain and swelling metrics in the context of symptomatic management for Osteoarthritis (OA).

Researchers evaluated whether the drug was associated with changes in gastrointestinal side effects compared to non-selective NSAIDs, and studies assessed tolerability for long-term use.

Clinical Efficacy Studies in OA

Pain Reduction

A randomized controlled trial (RCT) involving 450 OA patients investigated whether 12 weeks of treatment was associated with a change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. The average changes in scores were reported, and the drug's effect was examined across all dosage ranges tested.

A meta-analysis synthesizing data from seven trials evaluated whether the drug was associated with a change in joint function metrics (e.g., WOMAC stiffness subscale) compared to placebo.

Research Protocols

Research protocols examined the effect of various dosing regimens on changes in pain scores. Studies explored the association between the drug's use and the subsequent use of opioid analgesics in some patient groups.

Safety and Tolerability Profiles

Long-Term Safety Data

Long-term safety data were collected; studies assessed cardiovascular risk and reported findings when the drug was administered at the studied dosages. Study participants were monitored for signs of gastrointestinal bleeding, and research examined the drug's profile in adults with and without a history of major cardiac events.

Renal Function

Studies excluded people with severe renal impairment, and researchers noted the potential for the drug to affect kidney function.

Key Studies & References

1. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: a systematic review and meta-analysis

Common questions about Voltaren SR (FAQ)

Q: Can I drink alcohol while taking Voltaren SR?

Official regulatory warnings advise against the use of alcohol while taking diclofenac sustained-release (SR). Combining this medicine with alcohol significantly increases the potential risk of serious gastrointestinal side effects, such as stomach bleeding.

---

Q: What should I do if I miss a dose of Voltaren SR?

Patient information leaflets indicate that if a dose is forgotten, it can be taken when remembered, unless it is almost time for the next scheduled dose. Standard advice is to skip the missed dose in that scenario. It is generally advised that patients do not take a double dose to compensate for a forgotten one.

---

Q: Can I crush, chew, or split the Voltaren SR tablet?

No, the Voltaren SR tablet is a sustained-release formulation and must be swallowed whole with water. Official product information states the tablet must not be crushed, chewed, or split. This action would destroy the tablet's controlled-release mechanism, potentially causing the medicine to be absorbed too quickly.

---

Q: Is it safe to take Voltaren SR with other pain relievers like Tylenol (acetaminophen)?

The official regulatory labeling for Voltaren SR (diclofenac) does not list a major warning or contraindication for its co-administration with acetaminophen. However, it is important for patients to discuss all concomitant medications, including other over-the-counter pain relievers, with a healthcare professional.

---

Q: Can I take Voltaren SR for acute pain from an injury?

The approved indications for the sustained-release (SR) formulation of diclofenac are primarily for the management of chronic conditions, such as osteoarthritis. While the active ingredient addresses pain, the decision to use this specific modified-release product for acute (short-term) pain from an injury is a clinical one, determined by a healthcare professional.

---

Q: How long can I safely take Voltaren SR?

Regulatory guidance emphasizes that Voltaren SR should be used for the lowest effective dose for the shortest duration possible. Official safety warnings indicate that the risk of serious side effects, particularly cardiovascular and gastrointestinal events, may increase when the medicine is taken for longer periods.

How to Store and Dispose of Voltaren SR?

The official storage and disposal requirements for Voltaren SR (Diclofenac sustained-release tablets) are mandated by regulatory bodies to maintain product stability and safety.

Official Storage Requirements

• Temperature: Store the tablets at or below 25 C (controlled room temperature).
• Protection: The product must be protected from moisture and direct sunlight.
• Security: To prevent accidental ingestion, keep the medicine strictly out of the sight and reach of children and pets.
• Stability: Do not take the tablets after the expiry date (EXP) printed on the pack.

Mandated Disposal Protocol

Disposal of any unused or expired Voltaren SR should primarily utilize a drug take-back program. If a take-back option is unavailable, the medicine is not on the official FDA Flush List and must not be flushed down the toilet. The alternative method involves mixing the tablets (removed from their packaging) with an undesirable substance, such as dirt or used coffee grounds, and placing this mixture into a sealed container before throwing it into the household trash.